



IFW  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
( Case No. 02-249-E (400.042) )

In the Application of:

Beigelman et al.

Serial No.: 10/669,841

Filing Date: September 23, 2003

For: Oligonucleotide Mediated Inhibition of  
Hepatitis B Virus and Hepatitis C Virus  
Replication

Examiner: TBD

Group Art Unit: 1632

Confirmation No.: 2643

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:


- ☒ Supplemental Information Disclosure Statement;
- ☒ Supplemental Information Disclosure Statement (IDS) PTO-1449 Form;
- ☒ Copies of IDS Citations for S/N 10/669,841 (Total 2 other documents); and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.


3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on 8-25 2005.

By :

  
Lisa M.W. Hillman  
Reg. No. 43,673

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
300 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606  
TELEPHONE (312) 913-0001  
FACSIMILE: (312) 913-0002



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
( Case No. 02-249-E (400.042) )**

<b>In the Application of:</b>	)	
	)	
<b>Beigelman et al.</b>	)	
	)	<b>Examiner: TBD</b>
<b>Serial No.: 10/669,841</b>	)	
	)	<b>Group Art Unit: 1632</b>
<b>Filing Date: September 23, 2003</b>	)	
	)	<b>Confirmation No.: 2643</b>
<b>For: Oligonucleotide Mediated Inhibition of</b>	)	
<b>Hepatitis B Virus and Hepatitis C Virus</b>	)	
<b>Replication</b>	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a


representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Date: 8-25 2005

By:

  
Lisa M.W. Hillman  
Reg. No. 43,673

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-249-E  
(400.042)

Serial No.

10/669,841

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



(Use several sheets if necessary)

**Applicant:**  
Beigelman et al.

**Filing Date:**  
September 23, 2003

**Group:**  
1632

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,985,662		Anderson et al.			
	*	6,573,099		Graham			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

1.	Hammond et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature</i> , 2:110-119 (2001)
2.	Sugauchi et al., "Hepatitis B Virus of Genotype B with or without Recombination with Genotype C over the Precore Region plus the Core Gene," <i>Journal of Virology</i> , 76:5985-5992 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.